Table 2.
Methylation frequencies of the P16, RASSF1A, RPRM, and RUNX3 in the subjects and their performances in detection of gastric cancer with various stages
| Gene | TNM stage | Gastric cancer (n=96) | Controls (n=88) | p-value | AUC | S | Sp | PPV | NPV | Accuracy |
|---|---|---|---|---|---|---|---|---|---|---|
| Met (%) | Met (%) | |||||||||
| P16 | ||||||||||
| I+II | 12/34 (35.3%) | 14/88 (15.9%) | 0.026 | 0.60 | 0.35 | 0.84 | 0.46 | 0.77 | 0.71 | |
| III+IV | 28/62 (45.2%) | p<0.001 | 0.65 | 0.45 | 0.84 | 0.67 | 0.69 | 0.68 | ||
| I–IV | 40/96 (41.7%) | p<0.001 | 0.63 | 0.42 | 0.84 | 0.74 | 0.57 | 0.62 | ||
| RASSF1A | ||||||||||
| I+II | 8/34 (23.5%) | 0/88 | p<0.001 * | 0.62 | 0.24 | 1.0 | 1.0 | 0.77 | 0.79 | |
| III+IV | 24/62 (38.7%) | p<0.001 | 0.69 | 0.39 | 1.0 | 1.0 | 0.70 | 0.75 | ||
| I–IV | 32/96 (33.3%) | p<0.001 | 0.67 | 0.33 | 1.0 | 1.0 | 0.58 | 0.65 | ||
| RPRM | ||||||||||
| I+II | 16/34 (47.1%) | 6/88 (6.8%) | p<0.001 | 0.70 | 0.47 | 0.93 | 0.73 | 0.82 | 0.80 | |
| III+IV | 48/62 (77.4%) | p<0.001 | 0.85 | 0.77 | 0.93 | 0.89 | 0.85 | 0.87 | ||
| I–IV | 64/96 (66.7%) | p<0.001 | 0.80 | 0.67 | 0.93 | 0.91 | 0.72 | 0.79 | ||
| RUNX3 | ||||||||||
| I+II | 20/34 (58.8%) | 4/88 (4.5%) | p<0.001 | 0.77 | 0.59 | 0.95 | 0.83 | 0.86 | 0.85 | |
| III+IV | 36/62 (58.1%) | p<0.001 | 0.76 | 0.58 | 0.95 | 0.90 | 0.76 | 0.80 | ||
| I–IV | 56/96 (58.3%) | p<0.001 | 0.77 | 0.58 | 0.95 | 0.93 | 0.68 | 0.76 | ||
TNM: Tumor-Node-Metastasis; AUC: Area under the curve; S: Sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: Negative predictive value.
*
Fisher’s exact tests.